Literature DB >> 17296836

Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease.

Valerie Voon1, Teri Thomsen, Janis M Miyasaki, Minella de Souza, Ariel Shafro, Susan H Fox, Sarah Duff-Canning, Anthony E Lang, Mateusz Zurowski.   

Abstract

OBJECTIVE: To evaluate factors associated with pathological gambling (PG) in Parkinson disease (PD).
DESIGN: Case-control study.
SETTING: Outpatient tertiary clinic. Patients Twenty-one patients with idiopathic PD with PG after the patients began receiving medications compared with a consecutive sample of 42 patients with idiopathic PD without compulsive behaviors. MAIN OUTCOME MEASURES: Clinical features, comorbid psychiatric and substance use disorders, personality traits, and impulsivity scores.
RESULTS: Patients with PG had a younger age at PD onset (P = .006), higher novelty seeking (P<.001), medication-induced hypomania or mania (P = .001), impaired planning (P = .002), or a personal or immediate family history of alcohol use disorders (P = .002). Novelty seeking, a personal or immediate family history of alcohol use disorders, and younger age at PD onset accurately predicted PG at 83.7% in a logistic regression model, with the model accounting for 62% of the variance.
CONCLUSIONS: Patients with PD having a younger age at PD onset, higher novelty seeking traits, and a personal or family history of alcohol use disorders may have a greater risk for PG with dopamine agonists.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296836     DOI: 10.1001/archneur.64.2.212

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  92 in total

1.  Pramipexole and compulsive masturbation.

Authors:  Randy A Sansone; Mark Ferlan
Journal:  Psychiatry (Edgmont)       Date:  2007-09

2.  Modulation of frontostriatal interaction aligns with reduced primary reward processing under serotonergic drugs.

Authors:  Birgit Abler; Georg Grön; Antonie Hartmann; Coraline Metzger; Martin Walter
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

3.  Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists.

Authors:  Karina L Bienfait; Matthew Menza; Margery H Mark; Roseanne D Dobkin
Journal:  J Clin Neurosci       Date:  2010-02-19       Impact factor: 1.961

4.  Associations of specific psychiatric disorders with isolated focal dystonia, and monogenic and idiopathic Parkinson's disease.

Authors:  Susanne Steinlechner; Johann Hagenah; Hans-Jürgen Rumpf; Christian Meyer; Ulrich John; Tobias Bäumer; Norbert Brüggemann; Meike Kasten; Alexander Münchau; Christine Klein; Rebekka Lencer
Journal:  J Neurol       Date:  2017-04-11       Impact factor: 4.849

Review 5.  Impulse control disorders in Parkinson's disease: the role of personality and cognitive status.

Authors:  Michele Poletti; Ubaldo Bonuccelli
Journal:  J Neurol       Date:  2012-04-25       Impact factor: 4.849

6.  Long-term follow-up of impulse control disorders in Parkinson's disease.

Authors:  Eugenia Mamikonyan; Andrew D Siderowf; John E Duda; Marc N Potenza; Stacy Horn; Matthew B Stern; Daniel Weintraub
Journal:  Mov Disord       Date:  2008-01       Impact factor: 10.338

Review 7.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  B B Averbeck; S S O'Sullivan; A Djamshidian
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

Review 8.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  Increased motor impulsivity in a rat gambling task during chronic ropinirole treatment: potentiation by win-paired audiovisual cues.

Authors:  Melanie Tremblay; Michael M Barrus; Paul J Cocker; Christelle Baunez; Catharine A Winstanley
Journal:  Psychopharmacology (Berl)       Date:  2019-01-31       Impact factor: 4.530

Review 10.  Dopamine dysregulation syndrome. Hypothetical application of reward system stimulation for the treatment of anhedonia in Parkinson's disease patients.

Authors:  Tomoyoshi Kondo
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.